Rocket Pharmaceuticals Bolsa (NASDAQ: RCKT)

Rocket Pharmaceuticals (NASDAQ:RCKT) Bolsa

ROCKET PHARMACEUTICALS INC

Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

OTLK

RCKT

Descubre qué acciones sobrevendidas del sector salud tienen un RSI por debajo de 30 y podrían estar infravaloradas.

3 acciones estadounidenses de atención médica que podrían despegar este mes

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals Inc

ROCK TECH LINTHIUM INC by Rock Tech Lithium Inc.

Rock Tech Lithium Inc

Shopify Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) shares jumped 14.8% to $105.26 Monday afternoon. It was earlier <a href="https://ir.nasdaq.com/news-releases/news-release-details/shopify-inc-join-nasdaq-100-indexr-beginning-may-19-2025#:~:text=(Nasdaq%3A%20SHOP)%2C%20will,100%20Equal%20Weighted%E2%84%A2%20Index.">announced</a> the stock will join the Nasdaq-100 beginning May 19, replacing MongoDB. The move positions Shopify among the market's top tech names and could attract index-fund inflows.
What Else: The e-commerce platform <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45328107/shopify-shows-strong-global-momentum-but-guidance-raises-questions-on-profitability-path">reported</a> strong first-quarter results last Thursday, with revenue climbing 26.8% year-over-year to $2.36 billion, beating estimates. 
Gross merchandise volume <a href="https://www.benzinga.com/pressreleases/25/05/g45332641/shopify-inc-to-join-the-nasdaq-100-index-beginning-may-19-2025">rose 22.8%</a> to $74.75 billion, though adjusted EPS of 25 cents narrowly missed forecasts. Analysts cited robust growth in global merchant activity and resilient consumer demand as key drivers.
Sentiment also improved as the U.S. and China reached a <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation">landmark agreement</a> to slash tariffs, easing recession and inflation fears. With U.S. tariffs dropping from 145% to 30% and China's from 125% to 10%, global trade pressures are receding. 
Shopify noted minimal exposure to Chinese imports, suggesting limited direct impact from prior tariff risks. Analysts from Goldman Sachs and Piper Sandler expect continued growth into the second-quarter, with revenue forecast around $2.56 billion and EPS of 30 cents. Shopify's international momentum meanwhile remains a key pillar of its bullish outlook.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45353863/new-inflation-data-hits-tuesday-why-it-could-kill-fed-rate-cut-hopes">New Inflation Data Hits Tuesday: Why It Could Kill Fed Rate Cut Hopes</a>
<h2 class="wp-block-heading">How To Buy SHOP Stock</h2>
By now you're likely curious about how to participate in the market for Shopify &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Shopify, which is trading at $104.42 as of publishing time, $100 would buy you 0.96 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SHOP has a 52-week high of $106.35 and a 52-week low of $69.84.

SHOP

Why Shopify (SHOP) Stock Hit A New 52-Week High Today

Citigroup analyst Ygal Arounian maintains Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) with a Neutral and lowers the price target from $4 to $3.9.

Price Target

Analyst Ratings

Citigroup Maintains Neutral on Outbrain, Lowers Price Target to $3.9

Citigroup analyst Andrew Kaplowitz maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Buy and raises the price target from $127 to $133.

Citigroup Maintains Buy on Emerson Electric, Raises Price Target to $133

BofA Securities analyst Brad Sills maintained a Buy rating on Salesforce, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a <a target="_blank" href="https://www.benzinga.com/quote/CRM/analyst-ratings" rel="noreferrer noopener">price target of $350</a> on Monday.
Salesforce Sales Cloud is the company&#8217;s flagship offering, generating estimated subscription revenue of $7.9 billion in fiscal 2026. It is growing at an estimated 9% growth rate (constant currency), keeping pace with Sills&#8217; estimate for total company subscription revenue.
Over the years, Salesforce has expanded its offering from front office applications (both organically and inorganically) into other horizontal and vertical industry applications.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44908035/salesforces-investment-in-ai-and-data-cloud-boosts-long-term-growth-outlook-analyst-confident" rel="noreferrer noopener">Salesforce&#8217;s Agentforce AI, Data Cloud Strengthen Long-Term Growth Potential: Analyst</a>
Sales Cloud represents 21% of Sills&#8217; fiscal 2026 total subscription revenue and remains a core growth business.
Sills estimated that 40% of 135,000 Salesforce customers (not on freemium) are currently on Sales Cloud, which represents 4.9 million subscribers, a 10% penetration of the global addressable market (16.2 million sales-related workers per US Bureau of Labor Statistics and international = 2 x US).
Sales Cloud is priced per user per month based on the edition chosen, with each edition adding more advanced features. The per-user pricing allows each user to manage their login.
The Starter Suite ($25/user/month) includes only the basic feature for managing accounts and leads. In contrast, Einstein 1 Sales ($500/user/month) consists of all features, including Data Cloud and the Agentforce agentic AI offering.
Sales Cloud is one of Salesforce&#8217;s core growth businesses (along with Service Cloud), keeping pace with an estimated total subscription growth of 9%-10% and showing no slowdown.
Sales Cloud expansion deals are driven by Industry Cloud upsells, Revenue Cloud upsells, and the pull-through of more seats to support Revenue Cloud, Industry Cloud, and Data Cloud deployments.
Revenue Cloud is Salesforce&#8217;s CPQ solution. Channel feedback suggests Revenue Cloud and the migration from CPQ to Revenue Cloud Advanced (RCA) is driving additional growth for Sales Cloud.
Revenue Cloud is priced as an add-on to Sales Cloud for a $200 monthly subscription versus $165 for Sales Cloud Enterprise, representing an average 120% subscription uplift.
Sales Cloud is the core system of record for the entire Salesforce CRM stack.
Gartner forecasts Sales Cloud to sustain a 25% share of the $39 billion Sales CRM industry through 2027.
However, Salesforce is forecast to capture the most incremental industry growth, driven by advantages such as its integrated platform with internal sales systems, business intelligence features for projection analysis, and AI innovation.
Sills&#8217; calls with SI partners suggested that upselling premium-priced Industry Cloud (estimated 15% ASP uplift to enterprise customers) and Revenue Cloud (12% ASP uplift) represent key growth drivers for Sales Cloud.
Agentforce projects are also mentioned to widen the Sales Cloud user base in many enterprises, driven by demand for a more complete data set and user base.
Finally, while the softening macro pushes out Sills&#8217; near-term expectation for Agentforce revenue, the analyst noted that this would represent a material source of incremental Sales Cloud growth in the coming years.
In his base case Sales Cloud model, the analyst modeled a 5-year CAGR of 10%, assuming 7.5 million subscribers, or 13% user penetration of global sales TAM (up from 10% in fiscal 2026), ASP of $143 (from $135 in fiscal 2026) and 8% Agentforce revenue contribution to Sales Cloud growth.
In a reasonable upside case, the analyst arrived at a 5-year CAGR of 12%, assuming similar user penetration, ASP of $157 from higher Revenue Cloud and Industry Cloud penetration, and a 13% Agentforce contribution to growth.
Sills projected fiscal 2026 revenue of $40.31 billion.
Price Action: CRM shares are trading higher by 4.62% to $288.17 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45324239/apples-upcoming-chips-aim-to-challenge-meta-in-the-smart-glasses-battle-report" target="_blank" rel="noreferrer noopener">Apple&#8217;s Upcoming Chip Aims To Challenge Meta In Smart Glasses Battle: Report</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Reiteration

Tech

Salesforce Sales Cloud, AI Integration, And Cloud Upsells Drive Analyst Confidence In Long-Term Growth

Citigroup analyst Kyle Menges maintains Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) with a Buy and raises the price target from $320 to $350.

Citigroup Maintains Buy on Cummins, Raises Price Target to $350

<a href="https://www.benzinga.com/topic/s-p-500">The S&amp;P 500</a> is quietly pulling off a winning streak that even some bulls didn't see coming. For the second quarter in a row, the index has notched double-digit earnings growth &#8211; clocking in at 13.4% for the first quarter &#8211; leaving ETF investors in the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>) and Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) with something to cheer about.
According <a href="https://insight.factset.com/sp-500-earnings-season-update-may-9-2025?utm_source=Direct&amp;utm_medium=Email&amp;utm_campaign=FO-05-09-2025&amp;utm_content=httpsinsightfactsetcomsp500earningsseasonupdatemay92025">to</a> FactSet, 90% of S&amp;P 500 companies have reported results so far, and 78% of them beat earnings estimates &#8211; not only topping the 10-year average (75%) but also surpassing the five-year norm (77%). While the average earnings surprise of 8.5% came in just below the 5-year average (8.8%), it&#8217;s well ahead of the 10-year benchmark (6.9%).
Read Also: <a href="https://www.benzinga.com/25/05/45294428/wall-street-rallies-after-us-seals-first-trade-deal-you-better-go-out-and-buy-stock-trump-says">Wall Street Rallies After US Seals First Trade Deal: &#8216;You Better Go Out And Buy Stock,&#8217; Trump Says</a>
<h2 class="wp-block-heading">3 Sectors That Fueled Surprise Profits</h2>
This uptick didn't happen overnight. Since the end of the first quarter, earnings growth estimates have steadily climbed &#8211; from 7.1% on March 31 to 12.8% last week, now landing at a strong 13.4%. Much of the fuel came from surprise profits in Communication Services, Financials, and Health Care.
Eight out of eleven sectors are showing year-over-year earnings growth, with Health Care, Communications Services, Info Tech and Utilities leading the pack. Even more impressively, this is now the seventh straight quarter of earnings growth for the S&amp;P 500.
<h2 class="wp-block-heading">62% S&amp;P 500 Companies Delivered Revenue Beats</h2>
The revenue side of the story is more muted &#8211; 62% of companies beat top-line expectations (below the 5-year average of 69%), with aggregate revenue surprises averaging just 0.7%. But that still translates to a 4.8% revenue growth rate &#8211; the 18th consecutive quarter of sales growth.
Looking ahead, analysts are expecting earnings growth to cool slightly, with forecasts of 5.2%, 7.4%, and 6.7% for the second through fourth quarter. But with a forward P/E of 20.5 (above the 5- and 10-year averages), markets are already pricing in strength &#8211; or at least resilience.
For ETF investors watching SPY, IVV, or VOO, the S&amp;P 500 just sent a second bullish signal in a row: earnings are holding up &#8211; and then some.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45283497/federal-reserve-will-be-the-last-to-cut-says-expert-anticipating-4-cuts-in-2025-a-thaw-in-us-china-trade-dispute-is-good-news">Federal Reserve &#8216;Will Be The Last To Cut&#8217; Rates, Says Expert Who Still Expects Four Cuts In 2025</a></li>
</ul>
Photo: Shutterstock

Earnings

Earnings Beats

Broad U.S. Equity ETFs

ETFs

S&P 500 Q1 Earnings Jump 13.4% - SPY Investors Just Got Their Second Straight Double-Digit Surprise

WIIM

Constellation Energy shares are trading higher after BMO Capital raised its price target on the stock from $291 to $337.

Citigroup analyst Tyler Radke maintains Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) with a Neutral and lowers the price target from $37 to $25.

CFLT

Citigroup Maintains Neutral on Confluent, Lowers Price Target to $25

COIN

Coinbase Global shares are trading higher after Compass Point upgraded the stock from Sell to Neutral and several firms raised their respective price targets.

Citigroup analyst Alicia Yap upgrades PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) from Neutral to Buy and raises the price target from $127 to $165.

Upgrades

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Citigroup Upgrades PDD Holdings to Buy, Raises Price Target to $165

Canaccord Genuity analyst Joseph Vafi maintained a Buy rating on Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) and <a href="https://www.benzinga.com/quote/HUT/analyst-ratings" target="_blank" rel="noreferrer noopener">reiterated the $32 price forecast</a>.
The analyst writes that he sees consistent progress at Hut 8 under the leadership of CEO Asher Genoot and his team, who have been in place for approximately five quarters.
While the past year has primarily involved operational streamlining and realignment within Hut 8, Vafi believes the future holds more significant potential.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45324398/hut-8-analysts-still-bullish-despite-q1-miss-bets-on-american-bitcoin-hpc-ai-potential" rel="noreferrer noopener">Hut 8 Analysts Still Bullish Despite Q1 Miss; Bets On American Bitcoin, HPC/AI Potential</a>
Specifically, the analyst expects Hut 8 to navigate the complex challenge of maximizing the value of its Bitcoin (CRYPTO: BTC/USD) miner power portfolio and existing assets while simultaneously pursuing emerging opportunities in AI hosting without hindering either endeavor.
The analyst notes that the U.S. Bitcoin miners have grown via capital markets, but public markets often undervalue them despite strong returns and potential cost advantage over direct BTC buys.
The analyst adds that the company&#8217;s American Bitcoin vision might prioritize BTC accumulation over max mining output, potentially mirroring MicroStrategy&#8217;s treasury success.
Overall, the involvement of Eric and Donald Trump Jr. in American Bitcoin suggests that the new company&#8217;s activities will likely extend beyond solely mining Bitcoin, writes the analyst.
Today, Gryphon Digital Mining, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) disclosed a definitive stock-for-stock merger deal with American Bitcoin, a majority-owned subsidiary of&nbsp;Hut 8, <a target="_blank" href="https://www.benzinga.com//node/45347101" rel="noreferrer noopener">for an undisclosed amount</a>. Upon closing, the combined entity will operate under the American Bitcoin brand and is expected to trade on the Nasdaq under the ticker &#8220;ABTC.&#8221;
On Thursday, Hut 8 reported a loss per share of&nbsp;$1.30, below the estimated&nbsp;24 cents, and sales of&nbsp;$21.82 million&nbsp;fell short&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45279838/hut-8-reports-first-quarter-2025-results" rel="noreferrer noopener">of the estimated&nbsp;$33.28 million</a>.
Price Action: HUT shares are up 11.1% at $15.43&nbsp;at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45017261/bitcoin-mining-costs-jump-to-137000-per-coin-when-accounting-for-non-cash-expenses-coinshares" target="_blank" rel="noreferrer noopener">Bitcoin Mining Costs Jump To $137,000 Per Coin When Accounting For Non-Cash Expenses: CoinShares</a></li>
</ul>
Image via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Movers

GRYP

American Bitcoin Spin-Off, AI Ambitions To Boost Hut 8 Stock: Analyst

Prologis shares are trading higher after Scotiabank raised its price target on the stock from $97 to $100.

<a href="https://www.bloomberg.com/news/articles/2025-05-12/apple-plans-ai-powered-battery-management-mode-for-devices-in-ios-19?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-12/apple-plans-ai-powered-battery-management-mode-for-devices-in-ios-19?embedded-checkout=true</a>

General

AAPL

'Apple Plans AI-Powered Battery Management Mode for Devices in iOS 19'- Bloomberg

Ladenburg Thalmann analyst Mickey Schleien upgrades SLR Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRC#NASDAQ">SLRC</a>) from Neutral to Buy and announces $16.5 price target.

SLRC

Ladenburg Thalmann Upgrades SLR Inv to Buy, Announces $16.5 Price Target

Analysts are expressing views on Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) prior to its <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">earnings release on May 15</a>.
On Monday, Telsey Advisory Analyst Joseph Feldman maintained the Outperform <a href="https://www.benzinga.com/quote/WMT/analyst-ratings" target="_blank" rel="noreferrer noopener">rating and price forecast of $115.</a>
The analyst maintained the first quarter (Q1) estimates of 3.8% sales growth to $167.6 billion vs. FactSet consensus (FS) of $165.7 billion and adjusted EPS of $0.56 (FS: $0.57).
Feldman expects the quarter to benefit from grocery share gains, improving non-discretionary, e-commerce/marketplace progress, rollbacks, and broader wallet share (including higher-income).
Also Read: <a href="https://www.benzinga.com/markets/25/05/45342977/trumps-tariffs-reportedly-push-walmart-and-target-toy-suppliers-to-the-brink-of-closure-if-nothing-changes-well-be-crippled" target="_blank" rel="noreferrer noopener">Trump&#8217;s Tariffs Reportedly Push Walmart And Target Toy Suppliers To The Brink Of Closure: &#8216;If Nothing Changes, We&#8217;ll Be Crippled&#8217;</a>
The analyst adds that similar to recent trends at Amazon and Costco, Q1 sales could see a pull-forward in select categories like electronics.
Feldman writes that these positive factors are expected to be partially offset by selective consumer spending (especially on discretionary items) and unfavorable FX trends.
Overall, Feldman expects Walmart to navigate the current uncertain environment effectively.
For 2025, the analyst estimates sales growth of 4.0% to $708 billion, vs. the FS of 3.6% ($705 billion) and consistent with Walmart&#8217;s reiterated <a target="_blank" href="https://www.benzinga.com/news/guidance/25/04/44711688/walmart-maintains-steady-growth-forecast-despite-tariffs" rel="noreferrer noopener">April guidance of 3%-4% (constant currency)</a>.
The analyst sees adjusted EPS of $2.56 vs. FS of $2.60 and within <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">Walmart&#8217;s $2.50-$2.60 guidance range</a>.
The analyst anticipate continued selective consumer spending amid tariff-driven uncertainty regarding inventory and prices.
Meanwhile, additional tariffs, such as the current elevated rates on China, could necessitate significant actions, including potential price increases, to protect profits, adds the analyst.
B Of A Securities analyst Robert F. Ohmes kept the Buy rating with a price forecast of $120.
The analyst estimates adjusted EPS of $0.59 and a 3% increase in U.S. comparable sales for Q1, with comparable sales forecast indicating a deceleration compared to the fourth quarter.
Ohmes says that the estimates incorporate impacts from lapping the leap day last year (-100 basis point headwind to sales and -250 basis points to EBIT), the Vizio acquisition (a +15 basis point benefit to sales but a -70 basis point impact on EBIT), and foreign exchange.
The analyst writes that while not entirely shielded, Walmart is well-equipped to handle tariffs due to its strong supplier relationships, sophisticated pricing and automation strategies, effective inventory management, and the option to transition some directly sold (1P) imported goods to its third-party (3P) marketplace.
The analyst adds that given that groceries have a lower import exposure (they constitute 60% of Walmart&#8217;s U.S. sales), the company&#8217;s overall import exposure is limited to roughly one-third of its total U.S. business.
Price Action: WMT shares are down 0.4% at $96.26 at the last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45213125/bill-ackman-says-inflation-has-largely-been-wrung-out-pushes-for-temporary-pause-on-china-tariffs-to-shield-us-businesses" target="_blank" rel="noreferrer noopener">Bill Ackman Says Inflation Has &#8216;Largely Been Wrung Out,&#8217; Pushes For Temporary Pause On China Tariffs To Shield US Businesses</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Walmart Analysts: Strategy Curbs Price Hikes Despite Tariffs

CTRI

Centuri Holdings shares are trading lower following Q1 financial results.

Apogee Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) on Monday revealed interim data from its Phase 1b trial of APG808, a novel half-life extended IL-4Rα antibody, in patients with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45342426/apogee-therapeutics-announces-positive-interim-results-from-the-phase-1b-trial-of-apg808-its-novel" rel="noreferrer noopener">mild-to-moderate asthma</a>.
The Phase 1b double-blind, placebo-controlled, multiple-dose trial evaluated the safety and tolerability of APG808 in 22 adult patients with mild-to-moderate asthma.
The trial also evaluated fractional exhaled nitric oxide concentration (FeNO), TARC, and pSTAT6.
Participants were randomized 3:1, receiving 600mg of APG808 or placebo on day 1 and day 29.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44084945/apogee-therapeutics-investigational-atopic-dermatitis-potential-shows-strong-tolerability-extended-half-life-in-early-trial" rel="noreferrer noopener">Apogee Therapeutics&#8217; Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial</a>
The study showed that a multiple-dose regimen of APG808 was well tolerated in asthmatic patients through 12 weeks of available follow-up. The most common treatment-emergent adverse events (TEAEs) observed were headache, injection site erythema, and upper respiratory tract infections.
The company said there were no Grade 3 TEAEs or severe adverse events. No adverse events led to study discontinuation.
Also, multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation that is associated with asthma exacerbations. At 12 weeks, there was a maximal robust FeNO decrease from a baseline of 53% and a sustained FeNO decrease from a baseline of 50%.
APG808 also demonstrated a sustained and near-complete reduction in pSTAT6 and deep reduction of TARC, maintained through 12 weeks, two key Type 2 inflammatory biomarkers.
APG808&#8217;s optimized formulation, potential best-in-class PK profile, and durable FeNO suppression for 12 weeks support the potential for 2-month or longer maintenance dosing.
Apogee Therapeutics&#8217; reported cash, cash equivalents, and marketable securities were $681.4 million as of March 31, 2025.
Based on current operating plans, Apogee expects its existing cash, cash equivalents, and marketable securities will enable the company to fund its operating expenses into the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45342743/apogee-therapeutics-provides-business-update-pipeline-progress-and-reports-first-quarter-2025-fina" rel="noreferrer noopener">first quarter of 2028</a>.
Price Action: APGE stock is up 7.80% at $40.20 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45349416/blade-beats-q1-forecasts-as-jet-surge-short-flights-drive-gains" target="_blank" rel="noreferrer noopener">Blade Beats Q1 Forecasts As Jet Surge, Short Flights Drive Gains</a></li>
</ul>
Image via Shutterstock

Biotech

Health Care

APGE

Why Is Apogee Therapeutics Stock Trading Higher On Monday?

In April, Medicus Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) agreed to acquire all of Antev&#8217;s issued and outstanding <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">shares on a share exchange</a>.
Antev is a clinical-stage biotech company developing Teverelix, a next-generation GnRH antagonist, as the first in-market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to an enlarged prostate.
Medicus <a target="_blank" href="https://medicuspharma.com/medicus-pharma-ltd-announces-a-binding-letter-of-intent-to-acquire-antev-ltd-for-us75-million-in-a-share-exchange-transaction/" rel="noreferrer noopener">will</a> negotiate and enter into a definitive agreement with Antev in exchange for 2.67 million (or approximately 19%) shares.
Antev shareholders will be entitled to receive up to approximately $65 million in additional contingent consideration tied to potential future FDA Phase 2 and New Drug Application approvals.
The transaction is expected to close before the end of June.
D. Boral Capital on Monday raised the price target from $14 to $27, <a target="_blank" href="https://www.benzinga.com/quote/MDCX/analyst-ratings" rel="noreferrer noopener">with a Buy rating</a>.
&#8220;With no approved drug for AUR recurrence and an estimated $2 billion addressable U.S. market, Teverelix has the potential to become a first-in-class therapy with a differentiated safety and dosing profile,&#8221; said analyst Jason Kolbert. &#8220;We view this transaction as a savvy, de-risked pipeline expansion that materially enhances Medicus&#8217; near-commercial portfolio and positions the company for accelerated value creation.&#8221;
He added that Medicus is expanding into men&#8217;s health and urology by acquiring a first-in-class drug with low trial costs and a focused sales strategy targeting urologists.
Since this new program doesn&#8217;t overlap with Medicus&#8217; existing ones, the deal fits well with its overall strategy. It could add value, especially if Teverelix moves smoothly into Phase 3 trials and hits the market before 2030.
In March, Medicus Pharma announced a positively trending interim analysis for the SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (BCC).
The interim analysis shows the clinical study SKNJCT-003 is trending positively, with a proportion of subjects with complete clinical clearance of more than 60%.
The analysis also shows that the investigational product, D-MNA, was well tolerated for both dose levels, a low-dose group receiving 100 ug of D-MNA and a high-dose group receiving 200 ug of D-MNA, in all participants so far enrolled in the study, with no dose-limiting toxicities (DLTs) or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44162661/medicus-pharma-ltd-announces-positively-trending-interim-analysis-for-sknjct-003-phase-2-clinical-" rel="noreferrer noopener">serious adverse events (SAEs)</a>.
The company plans to submit the interim analysis to the United States Food and Drug Administration (FDA) as part of a package seeking a Type C meeting with the FDA in Q2 2025.
Price Action: MDCX stock is up 15.8% at $5.31 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45353362/surgery-partners-misses-q1-marks-but-sticks-to-2025-outlook" target="_blank" rel="noreferrer noopener">Surgery Partners Misses Q1 Marks But Sticks To 2025 Outlook</a></li>
</ul>
Photo: Shutterstock

MDCX

Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

DOLE

Dole shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

Loop Capital analyst Jeffrey Stevenson maintains Installed Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBP#NYSE">IBP</a>) with a Buy and lowers the price target from $210 to $200.

Loop Capital Maintains Buy on Installed Building Prods, Lowers Price Target to $200

Press Releases

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Comments

Rocket Pharmaceuticals

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL